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Background: Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25–30% of
functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However,
tumors are resistant to therapy in 5–18% of patients.
Methods: The exomes of six responsive prolactinomas and six resistant prolactinomas were analyzed by
whole-exome sequencing.
Results: Using stringent variant calling and filtering parameters, ten somatic variants that were mainly associated
with DNA repair or protein metabolic processes were identified. New resistant variants were identified in multiple
genes including PRDM2, PRG4, MUC4, DSPP, DPCR1, RP1L1, MX2, POTEF, C1orf170, and KRTAP10-3. The expression of
these genes was then quantified by real-time reverse-transcription PCR (RT–qPCR) in 12 prolactinomas and 3 normal
pituitary glands. The mRNA levels of PRDM2 were approximately five-fold lower in resistant prolactinomas than in
responsive tumors (p < 0.05). PRDM2 protein levels were lower in resistant prolactinomas than in responsive
tumors, as determined by Western blotting and immunohistochemical analysis (p < 0.05). Overexpression of PRDM2
upregulated dopamine receptor D2 (D2DR) and inhibited the phosphorylation of ERK1/2 in MMQ cells. PRDM2
showed a synergistic effect with BRC on the inhibition of prolactin (PRL) secretion and MMQ cell viability, and low
PRDM2 expression was associated with tumor recurrence.
Conclusions: PRDM2 downregulation may play a role in dopamine-agonist resistance and tumor recurrence in
prolactinomas.
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Prolactinomas account for 25–30% of functioning pituit-
ary tumors, with an estimated prevalence of 100 cases per
100,000 individuals [1-3]. Pharmacological intervention is
the first-line treatment and involves the use of dopamine
agonists (DAs) to reduce tumor size and prolactin level.
BRC, the oldest drug for the medical treatment of prolac-
tinomas, was introduced into clinical practice approxi-
mately 30 years ago [1,4] and is the only commercially
available DAs in China. In 80–90% of patients with* Correspondence: zyz2004520@yeah.net
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unless otherwise stated.microprolactinomas and 70% of individuals with macro-
prolactinomas, BRC treatment controls hyperprolactine-
mia, restoring gonadal function and reducing tumor size.
Side effects of BRC include nausea, dizziness (ortho-
static hypotension), nasal stuffiness, difficulty concen-
trating, depression, psychosis, and peripheral vasospasm
and so on [1].
Resistance to BRC, defined as the absence of normal-
ization of prolactin (PRL) levels despite a 15 mg daily
dose of BRC during at least 3 months, has been observed
in 5–18% of prolactinomas according to the literature
[3,5]. The mechanisms underlying BRC resistance of pro-
lactinomas are not fully understood, although such resist-
ance to BRC correlates with reduced binding to the D2is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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factor. Resistance to BRC therapy may involve defects in
D2 dopamine receptor expression and possibly its post-
transcriptional splicing [6,7]. The ability to predict the
degree and extent of BRC resistance would enable the
design of personalized treatment regimens. Lack of thera-
peutic response to BRC may be an indication for surgery
or radiation therapy. In the present study, we used strin-
gent variant calling and filtering parameters and identified
10 somatic mutations mainly associated with DNA repair
or the protein metabolic process by using whole-exome
sequencing in combination with homozygosity mapping
in a comparative analysis of BRC-responsive and BRC-
resistant prolactinomas. We describe a new candidate
gene associated with BRC resistance in prolactinomas,
PRDM2, and show that the protein and mRNA levels of




Samples from six BRC-responsive prolactinomas and six
BRC-resistant prolactinomas were obtained from the bio-
bank of Beijing Neurosurgical Institute. And these patients
underwent endoscopic trans-sphenoidal surgery between
December 2008 and January 2011 at Tiantan Hospital,
Beijing, China. Informed consent was obtained from pa-
tients using protocols approved by IRB of Beijing Tiantan
Hospital Affiliated to Capital Medical University (KY2013-
015-2). Pituitary prolactinomas which were obtained from
12 patients (8 men and 4 women, mean age 37.4 years,-
range 15–63 years) without a family history of endocrine
neoplasia were characterized on presurgical clinical and
biochemical findings and morphological and immunohis-
tochemical analysis of removed tissue samples (Table 1).Table 1 Patients classification according to their response to
Patient
number
Serum PRL levels (μg/ml) Tumor siz
Before BRC With BRC Normal?
1 928 3.9 YES 2
2 4843 15 YES 2.5
3 122.3 3.18 YES 1.8
4 899 7.6 YES 4.5
5 3117 9.2 YES 2.5
6 3830 15.5 YES 2
7 975 165 NO 3.5
8 >6000 268 NO 3
9 182 83.2 NO 2
10 >6000 68.2 NO 2.5
11 2899 128.6 NO 5
12 168 150 NO 0.8Resistant tumors were defined as those from patients
whose serum PRL levels remained abnormally high after
at least 3 months of treatment with a daily dose of at least
15 mg BRC(1; 3). The tumors did not have features of
atypia, and they constituted the discovery set of tumors
for exome capture and DNA sequence analysis. Additional
twenty-four pituitary prolactinomas, histologically con-
firmed, were obtained from 8 women and 16 men (mean
age 61 years, range 17–71 years), and these constituted
the validation set (Table 2).
Exome capture, DNA sequencing, and bioinformatics
analysis
Total DNA was extracted from prolactinomas using the
QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany).
An aliquot containing 5 μg of genomic DNA was puri-
fied and quantified from each specimen. Exome enrich-
ment was performed by using an ABI SOLiD optimized
SureSelect Human All Exon kit (Agilent, Santa Clara, CA,
USA), which included the exonic sequences of ~18,000
genes, covering a total of 37 Mb of genomic sequences.
The enriched exome libraries were then amplified by
emulsion PCR(ePCR), according to the manufacturer’s in-
structions (Life Technologies, Carlsbad, CA, USA), based
on a library concentration of 0.5 pM. The PCR products
were then sequenced on a SOLiD5500 sequencer (Life
Technologies); one quad of a SOLiD sequencing slide was
required for each sample.
Color-space reads were mapped to the hg19 reference
human genome using SOLiDBioScope software (Life
Technologies), which is suitable for a repetitive mapping
approach. Single-nucleotide polymorphisms (SNPs) were
then called using the diBayes algorithm with conservative
default call stringency [8]. We excluded known SNPs avail-


















Table 2 Relationship between PRDM2 mRNA levels in
prolactinomas and various clinical parameters
PRDM2 mRNA levels
Feature High* Low Chi-square p-Value
All cases 12 12
Patient’s age
≥50 5 6 0.168 0.682
<50 7 6
Patient’s gender
Male 9 7 0.756 0.385
Female 3 5
Serum PRL levels
≥435 μg/ml ** 4 5 0.178 0.673
<435 μg/ml 8 7
Tumor size
≥2 cm 5 7 0.670 0.413
<2 cm 7 5
Recurrence***
Yes 4 10 6.511 0.011
No 8 2
Resistance to BRC****
4 9 4.332 0.037
8 3
*The median expression level was used as the cutoff. Low PRDM2 mRNA levels
were defined as values below the 50th percentile of the 12 patients; values at
or above the 50th percentile were classified as high levels.
**The median serum PRL level was used as the cutoff: 435 μg/ml. Low serum
PRL levels were defined as values below the 50th percentile of the 12 patients;
values at or above the 50th percentile were classified as high levels.
***Recurrence was defined as the discovery of an elevated PRL level at any
time in the postoperative surveillance period after an initial remission.
****Resistant tumors to BRC were defined as those from patients whose serum
PRL levels remained abnormally high after at least 3 months of treatment with
a daily dose of 15 mg BRC.
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RNA extraction and real-time reverse-transcription
quantitive PCR (RT–qPCR)
Total RNA was extracted from prolactinomas (~50 mg)
stored in liquid nitrogen using the TRIzol Reagent (Life
Technologies). The primers used in real-time reverse-
transcription PCR (RT-qPCR) are listed in (Table 3). RT-
qPCR was performed as described previously [3], using
Applied Bio-systems 7500 Fast System (Life Technologies).
The fold-change in differential expression for each gene
was calculated using the comparative CT method (also
known as the 2−ΔΔCT method) as previously described [9].
Plasmid constructs
The human PRDM2 cDNA was obtained by reverse
transcriptase-polymerase chain reaction from human brain
RNA with primers (forward 5’-TCTGCTGTTGACAAG
ACCC-3’, reverse 5’-GCATCAATGCACATCCATC -3’)
designed according to the prdm2 sequence published in
GenBank (NM_001135610.1). The cDNA was directionally
cloned into the pCMV6 plasmid (Invitrogen). The orienta-
tion of the WTcDNA was verified by DNA sequencing.
Assessment of cell viability
To evaluate the effect of PRDM2 on cell viability, 1 × 104
MMQ cells were transfected with PRDM2 for 24 h, 48 h
and 72 h in 96-well plates. A total of 20 μl of 5 mg/ml 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT)
was added into each well to continue the culture for an-
other 4 h. Culture medium was discarded and dimethyl
sulfoxide was added at 100 μl/well. The mixture was
shaken for 10 min at a constant temperature of 37 C be-
fore absorbance measurement.
Concentration of cell PRL secretion assays using ELISA
To evaluate the effect of PRDM2 on PRL secretion, 1 ×
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corresponding solvent added to control wells was followed
by culture for 24 h and centrifugation to collect the super-
natant. Then following the directions of the rat PRL ELISA
kit manual, the concentrations of PRL were estimated from
a standard curve of known PRL concentrations.Immunohistochemical analysis of prolactinoma specimens
The immunohistochemical SABC method was used as
described previously [8]. Prolactinoma and pituitary gland
specimens were sectioned to a thickness of 5 μm in paraf-
fin wax. The sections were subjected to gradient dewax-
ing, removed to water, treated with fresh 3% hydrogen
peroxide at room temperature for 10 min, and washed
with PBS (PH 7.2) 3 times for 5 min each. For microwave
repair, the specimens were placed in 0.01% citric acid
(pH 6.0), kept warm in a microwave oven (600 W) for
10 min, allowed to cool to room temperature, and washed
once with PBS. Antibody repair solution I was added at
room temperature for 10 min, and then washed 3 times
with PBS for 5 min each time. Primary PRDM2 (RIZ1)
antibody was added at a 1:200 dilution and incubated at
4°C overnight. The daylight™ conjugated affinipure sec-
ond antibody with fluorescence was added at room
temperature for 1 h followed by 3 washes with PBS for
5 min each time. SABC was added for 20 min and then
washed with adequate PBS. Sections were mounted with
Prolong Gold Antifade reagent with 4′,6-diamidino-2-
phenylindole (DAPI) (Invitrogen). Sections were analyzed
with a LEICA-TCS-SP5II to estimate the percentage of
DAPI-stained cells displaying PRDM2 immunoreactivity.Table 4 Genes potentially related to BRC resistance in
prolactinomas
Gene GenBank ID Encoded protein
C1orf170 BC006300 Uncharacterized protein, chromosome
1 ORF 170
DPCR1 NM_080870 Diffuse panbronchiolitis critical region
protein 1
DSPP NM_014208 Dentin sialophosphoprotein
KRTAP10-3 NM_198696 Keratin associated protein 10-3
POTEF NM_001099771.2 POTE ankyrin domain family, member F
MUC4 NM_138297.4 Mucin 4, cell surface associated
MX2 NM_002463 Myxovirus (influenza virus) resistance
protein 2
PRDM2 NM_001007257.2 PR domain containing 2, with ZNF
domain
PRG4 NM_005807. Proteoglycan 4 (PRG4), transcript
variant A
RP1L1 NM_178857 Retinitis pigmentosa 1-like 1 proteinSDS–PAGE and Western blot analyses
Prolactinomas and normal pituitary specimens were
lysed in TNE buffer (50 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA; all from Sigma-Aldrich) containing
1% Nonidet P-40 (Calbiochem) with protease and phos-
phatase inhibitor cocktails (Roche). Total extracts were
centrifuged at 12000 × g for 30 min at 4°C, and the protein
concentration of the supernatant was determined with a
BCA protein assay kit (Pierce Biotechnology). For western
blot analysis, 40 μg of lysate per lane was loaded onto 4–
12% Bis-Tris SDS-PAGE gels, separated electrophoretic-
ally, and blotted onto polyvinylidene fluoride (PVDF)
membranes. Different blots were incubated with anti-
bodies against D2DR (1:2000, Abcam), p-ERK1/2 (1:1000,
CST), PRL (1:1000, Santa-Cruz), T-ERK1/2(1:1000, CST),
PRDM2 (1:500, Abcam) and β-actin (Sigma) followed by
secondary antibodies tagged with horseradish peroxidase
(Santa Cruz Biotechnology). Blots were visualized by en-
hanced chemiluminescence, and densitometry was per-
formed with a Versadoc XL imaging apparatus (Bio-Rad).
Analysis of β-actin levels was used as a loading control.Statistical analysis
All the statistical analyses were performed using SPSS
version 20.0. For comparisons, one-way analyses of vari-
ance, chi-squared tests, Wilcoxon rank-sum test and two-
tailed Student’s t-tests, were carried out as appropriate.
Binary logistic regression was performed to identify inde-
pendent factors related to prolactinoma recurrence.
Results
Identification of variant genes by whole-exome
sequencing
The exomes of six BRC-responsive prolactinomas and
six BRC-resistant prolactinomas were analyzed by whole-
exome sequencing which yielded excellent target region
coverage with approximately 71% of the exome covered
to a depth of at least ten-fold between the somatic variant
calling algorithm and confirmatory sequencing. Several
prioritization steps were taken to decrease the number of
genetic variants and to find the potentially pathogenic
variants [10]. Approximately 90% of single-nucleotide vari-
ants (SNVs) resulted in missense amino-acid changes,
whereas the remaining approximately 10% were synonym-
ous changes. More than 70% of the SNVs occurred as C:
G–T: A transitions, and less than 30% were transversions.
Using stringent variant calling and filtering parameters,
119 somatic variants were identified in these specimens. A
comparison with the NCBI dbSNP, with recently released
SNP data from other groups and with in-house SNP data
confirmed that >90% of the identified variants were previ-
ously reported SNPs that did not seem to explain BRC re-
sistance of prolactinomas. Ten variant genes were selected
for further study: C1orf170, DPCR1, DSPP, KRTAP10-3,
POTEF, MUC4, MX2, PRDM2, PRG4, RP1L1 (Table 4) and
the original data were shown in Additional file 1: Table S1.
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We used real time quantitative PCR (RT–qPCR) to test
whether BRC resistance in prolactinomas was associated
with differences in the expression levels of any of 10 vari-
ant genes. Indeed, the mRNA levels of C1orf170, DPCR1,
KRTAP10-3, PRDM2 and RP1L1 were 50% lower in resist-
ant tumors than in responsive tumors. In particular,
PRDM2 mRNA levels were approximately five-fold lower
in resistant prolactinomas than in the responsive tumors
(p < 0.05). By contrast, the mRNA levels of DSPP, PRG4,
MUC4, POTEF and MX2 were higher in resistant prolacti-
nomas than in the responsive tumors (p > 0.05). Mean ex-
pression levels of the 10 genes are shown in Figure 1 and
Table 5 (statistical method: two-tailed Student’s t tests).
Identification of candidate driver mutations
Somatic mutations in genes previously associated with
pituitary tumorigenesis including AIP, BMP-4, CDKN1B,
CDKN2A, CDKN2C, Cyclin D1, D2R, GADD45G, Gsp,
MEG3a, MEN1, p53, Pdt-FGFR4, PKC, PRKAR1A, PTTG,
RAS, SSTR2/SSTR5, WIF-1 and ZAC1[8,11] were not de-
tected. To identify putative driver mutations, further ana-
lysis of each of the somatic variants was performed. We
hypothesized that putative driver mutations would typic-
ally: 1) have a deleterious effect on protein function; 2) be
present at sufficient allele frequency to represent likely
heterozygous or homozygous changes; and 3) be involved
in biological processes relevant to tumorigenesis [12].
Using these criteria, PRDM2 (retinoblastoma interacting
zinc-finger protein, RIZ) was selected for further evalu-
ation. The PRDM2 gene was isolated in a functionalFigure 1 RT-qPCR analysis of 10 variant genes in BRC-responsive and BRC-
statistically significant.screening for Rb-binding proteins. The PRDM2 gene is
one of the candidate tumor suppressor genes on chromo-
some 1p. Moreover, inactivation of the PRDM2 gene by
promoter hypermethylation has been reported in breast,
liver, and gastric carcinomas [13,14]. To investigate the
potential role of PRDM2 in BRC resistance, we measured
the level of PRDM2 expression by western blotting and
immunohistochemistry in six resistant prolactinomas, six
sensitive prolactinomas and three normal pituitary glands.
The PRDM2 protein level in the BRC-resistant group was
approximately 24.6 ± 5.2% of that in the normal pituitary
gland (p < 0.01); however, the PRDM2 protein level in the
BRC-responsive group was 78.3 ± 6.1% of that in the nor-
mal pituitary gland (p < 0.05) (Figure 2). PRDM2 protein
levels were obviously lower in resistant prolactinomas
than in the responsive tumors (p < 0.05). Confocal images
showed that the number of PRDM2-positive puncta in
BRC-resistant prolactinomas was lower than that of the
normal pituitary and sensitive prolactinomas (Figure 3).
And the levels of PRDM2 mRNA in BRC-resistant prolac-
tinomas were about five lower than in the responsive tu-
mors (p < 0.05), and about eight fold lower than in normal
pituitary glands (Figure 4).
PRDM2 showed a synergistic effect with BRC on the
inhibition of PRL secretion and MMQ cell viability
BRC is derived by semisynthesis and has D2 receptor agon-
ist and D1 receptor antagonist properties. We found that
overexpression of PRDM2 could increase the D2R level
and PRL level of MMQ cells by Western blot (Figure 5A).
In additional, PRDM2 could reduce the phosphorylation ofresistant prolactinomas. Only the differential expression of PRDM2 was
Table 5 Differential expression folds of genes
Responsive Resistant p value
PRDM2 0.260138247 0.05833261 0.020
PRG4 0.000109963 0.000281276 0.700
MUC4 0.010466577 0.015666494 0.700
DSPP 0.010298289 0.021137023 0.513
DPCR1 0.3257084 0.154926532 0.060
RP1L1 0.023944092 0.006293673 0.400
MX2 0.108311332 0.18653675 0.807
POTEF 0.146750534 0.150689894 0.655
C1orf170 0.043853399 0.024682049 0.150
KRTAP10-3 0.003738342 0.006845497 0.827
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cells (Figure 5B).
To evaluate the effect of PRDM2 on PRL secretion, 1 ×
106 MMQ cells were transfected with PRDM2 (1 μg) for
24 h. Another 24 h was cultured with BRC (40nM) to test
wells and isometric DMSO as control wells. BRC could in-
hibit the PRL secretion and MMQ cell viability. We found
that PRDM2 showed a synergy inhibition with BRC on
PRL secretion and MMQ cell viability (Figure 6).
Low PRDM2 mRNA levels is associated with tumor
recurrence in prolactinomas
Between 2008 and 2013, 24 patients with prolactinomas
were enrolled in our study. Follow-up periods ranged
from 6 months to 5 years (mean 4.0 years). The median
expression level was used as the cutoff. Low PRDM2
mRNA levels were defined as values below the 50th per-
centile of the 12 patients; values at or above the 50th
percentile were classified as high levels. We then asked
whether low PRDM2 mRNA levels in prolactinomas
were associated with any clinical parameters (Table 2.)
(Chi squared tests). There was no significant correlationFigure 2 The protein level of RIZ1 in groups.between PRDM2 mRNA levels and age, gender, tumor
size or PRL serum levels. However, low PRDM2 mRNA
levels were more frequently observed in recurrent tu-
mors (p = 0.011) and BRC-resistant tumors (p = 0.037).
Recurrence was defined as the discovery of an elevated
PRL level at any time in the postoperative surveillance
period after an initial remission [1]. Furthermore, binary
multivariate regression revealed that low levels of PRDM2
mRNA were independently associated with tumor recur-
rence (odd ratio [OR] 0.065, 95% confidence interval [CI]:
0.05–0.832, p = 0.036).
Discussion
Previous studies showed that some DA-resistant prolac-
tinomas have reduced dopamine d2 receptor density
using different methods [15,16]. The proportion of D2R-
encoding mRNA corresponding to the D2S isoform was
lower in resistant prolactinomas than in responsive tu-
mors have demonstrated by other studies [17,18]. Whole-
exome sequencing identified sequence variants associated
with 10 genes, not previously implicated in DA-resistant
prolactinomas. In addition, our analysis identified somatic
variants in established oncogenes, tumor suppressor genes
and genes associated with DNA repair and protein meta-
bolic processes.
In the present study, PRDM2 mRNA levels were ap-
proximately five-fold lower in resistant prolactinomas
than in the responsive tumors (p < 0.05). PRDM2 protein
levels were significantly lower in resistant prolactinomas
than in the responsive tumors (p < 0.05). In addition,
Confocal images showed that the number of PRDM2-
positive puncta in BRC-resistant prolactinomas was lower
than that of the normal pituitary and sensitive prolactino-
mas (p < 0.05). We found that PRDM2 showed a synergy
inhibition with BRC on PRL secretion and MMQ cell via-
bility. Further analysis of our data confirmed that low
levels of PRDM2 were more frequently observed in recur-
rent tumors. Furthermore, binary multivariate regression
analysis revealed that low PRDM2 expression level was in-
dependently associated with prolactinoma recurrence (OR
0.065; 95% CI: 0.05–0.832; p = 0.036).
Pellegrini et al. [15] in 1989 found that D2R levels
were lower in dopamine resistant prolactinomas. And
then, the same group showed also a lower expression of
pituitary specific PIT1 (POU1F1) transcription factor in
dopamine resistant prolactinomas [18]. Raverot et al.
[19] found already seven genes mRNA level variation,
notably PPTG and CCNB1, were associated with tumor
recurrence or progression. Delgrange et al. [20] reported
that resistant prolactinomas tend to be more invasive
and to recur more often than responsive tumors. Fur-
thermore, recurrent prolactinomas were more likely to
be resistant to the drug therapy. Some authors [3,18,21]
reported that resistant prolactinomas tend to be more
Figure 3 The expression level of RIZ1 in different groups through Confocal. A: Normal. B: BRC-Responsive prolactinomas; C BRC-Resistant
prolactinomas. Green: RIZ1 Blue: DAPI. Bar: 50 μM.
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Furthermore, recurrent prolactinomas are more likely to
be resistant to drug therapy.
Buyse et al. first found PRDM2 by retinoblastoma (Rb)
probes in 1995, while performing a functional screen
for Rb, and observed that it was able to interact with Rb
[22]. Fluorescent in situ hybridization showed that the
PRDM2 gene is located on human chromosome 1p36.
There are two variants of PRDM2, RIZ1 and RIZ2, ac-
cording to two alternative initial locations [23,24]. The
sequences of RIZ1 and RIZ2 are same, except the pres-
ence of a PR domain in RIZ1. Generally, RIZ1 is refers
to PRDM2 protein. The PR domain in RIZ1 is named
after the PRDI-BF1-RIZ1 region and contains about 100
amino acids. The role of the structure is to stabilizeFigure 4 Mean PRDM2 mRNA levels in BRC-responsive and BRC
resistant prolactinomas and in normal pituitary. PRDM2 expression
was measured by RT-qPCR in 6 BRC-responsive prolactinomas, 6 BRC
resistant prolactinomas and 6 normal pituitary glands. Horizontal lines
above the bars represent standard deviations (statistical method:
one-way analyses of variance).chromosomal structures and, therefore, mediate gene ex-
pression [25]. The presence or absence of a PR domain re-
sults in the differential expression of proteins at an early
stage of tumorigenesis, which provides a mechanism for
tumor initiation [26]. Some reports have demonstrated
that RIZ1 is able to inhibit tumor development and is
thought to be a tumor suppressor gene [14,27,28]. Fur-
thermore, because RIZ1 closely interacts with Rb, which
induces the arrest of tumor cells in the G2/M phase
resulting to cell death, up-expression of RIZ1 may lead to
arrest of tumor [26].
As a new tumor suppressor, PRDM2 has been analyzed
in a few reports, which have attempted to explain the rea-
sons the gene is inactivated in cancer cells. Genetic and
epigenetic changes are thought to be responsible [29,30].
According to a genetic perspective, PRDM2 may be
down-regulated by chromosomal instability and micro-
satellite instability, as well as frame-shift mutations,
point mutations and heterozygote deficiency [14,29,31].
From an epigenetic perspective, the deactivation of
PRDM2 may occur due to promoter methylation and
histone acetylation [32]. Changes to chromosome 1p36,
on which PRDM2 is located, are also associated with nu-
merous types of cancer, including breast cancer, ovarian
cancer, liver cancer, colorectal cancer, chronic myeloid
leukemia, melanoma, chromaffin tumor and neuroblast-
oma [29]. In all these tumor types, the tumor tissue sam-
ples and cancer cell lines displayed low expression levels
or deficiency of PRDM2. In our study, we found the low
PRDM2 level in BRC-resistance prolactinomas because of
inser mutation (chr1:14106398, TCC). Overexpression of
PRDM2 in MMQ cells could up-regulate the D2DR lelvel,
and we speculates that PRDM2 is potential synergy inhib-
ition with BRC through the PRL secretion and cell viabil-
ity tests of MMQ cells.
Figure 5 Overexpression PRDM2 could increase the D2R level and inhibit the cell proliferatin of MMQ cells. A: Overexpression PRDM2 could
increase the D2R level and reduce the phosphorylation of ERK1/2 in MMQ cells. B: Overexpression of PRDM2 could inhibit the cell proliferation of
MMQ cells. n = 3 * compared to Control group.
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[33]. The BRC-resistance of prolactinomas is associated
with several processes including drug efflux by transporters,
inactivation by detoxifying enzymes, altered expression of
pro-/anti-apoptotic proteins or tumor suppressors, and in-
creased activity of DNA repair mechanisms [34,35]. In
many cases, only single base pair changes are required to
activate, silence, or functionally alter critical genes (e.g.,
proto-oncogenes, tumor suppressor genes) in a cell type-,
differentiation stage-, and carcinogen-specific manner. The
DNA repair machinery can be seen as a “caretaker” [36] in
charge of preserving the integrity and stability of the gen-
ome. Specific base substitutions (point variants) in genomic
DNA may be caused by endogenous and exogenous mech-
anisms and DNA-reactive agents. In the present study, 10
variants were associated with DNA repair or DNA meta-
bolic processes, including PRDM2, PRG4, MUC4, DSPP,Figure 6 PRDM2 showed a synergy effect with BRC on the inhibition of PR
PRDM2 and BRC. *compared to Control group # compared to BRC group B
Control group # compared to PRDM2 group.DPCR1, etc. Frame-shift mutations of the PRDM2 gene are
also common in microsatellite instability-positive tumors
and truncate a PR-interacting domain [23].
Conclusion
In summary, our results suggest that low levels of
PRDM2 may contribute to promote drug resistance
and tumor recurrence of prolactinomas in an as yet
unknown manner. Further work will be required to ex-
tend the potential links between PRDM2, drug resist-
ance and tumor recurrence. Our results demonstrate
that whole-exome sequencing will be particularly valu-
able for gene discovery under conditions in which map-
ping has been confounded by locus heterogeneity and
uncertainty about the boundaries of diagnostic classifi-
cation, pointing to a bright future for its broad applica-
tion to medicine.L secretion and MMQ cell viability. A: The PRL level of MMQ cells after
: The cell viability of MMQ cells after PRDM2 and BRC. *compared to
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Additional file 1: Table S1. The original data of 10 genes with
mutations in prolactinomas.
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